Literature DB >> 16302177

Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy.

B J Moran1, A Mukherjee, R Sexton.   

Abstract

BACKGROUND: Peritoneal malignancy is common at the terminal stages of many intra-abdominal neoplasms. In selected patients a novel approach of complete macroscopic tumour removal by extensive surgical cytoreduction, combined with intraperitoneal chemotherapy, provides a possibility of cure. Initial experience with 100 consecutive laparotomies is reported.
METHODS: Between 1994 and 2002, 218 patients with peritoneal malignancy were referred to a specialized unit. One hundred underwent laparotomy, of whom 85 had a primary appendiceal tumour. Treatment aims were complete macroscopic tumour excision combined with intraoperative intraperitoneal chemotherapy.
RESULTS: Sixty-five patients had complete macroscopic tumour excision, 28 palliative major cytoreduction and seven were inoperable. The overall mortality rate was 8 per cent. The most common complications were pulmonary (25 per cent) and wound (14 per cent) infection. At a median follow-up of 30 (range 3-113) months, 44 of 51 patients with primary appendiceal tumours who had complete macroscopic cytoreduction were alive and 36 were disease free.
CONCLUSION: Cytoreduction combined with intraperitoneal chemotherapy is an emerging technique with promising results in selected patients with peritoneal malignancy. Copyright 2005 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16302177     DOI: 10.1002/bjs.5210

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.

Authors:  Álvaro Arjona-Sánchez; Francisco C Muñoz-Casares; Sebastián Rufián-Peña; Rafael Díaz-Nieto; Ángela Casado-Adam; María J Rubio-Pérez; Rosa Ortega-Salas
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

Review 2.  Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

Authors:  Csilla Hasovits; Stephen Clarke
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

3.  Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Robert M Smeenk; Vic J Verwaal; Ninja Antonini; Frans A N Zoetmulder
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

4.  A prospective evaluation of venous thromboembolism in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Kathryn Lanuke; Lloyd A Mack; Walley J Temple
Journal:  Can J Surg       Date:  2009-02       Impact factor: 2.089

Review 5.  Therapeutic options for peritoneal metastasis arising from colorectal cancer.

Authors:  Gabriel Glockzin; Hans J Schlitt; Pompiliu Piso
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-08-06

6.  Pseudomyxoma peritonei extending to the lower extremity: a case report.

Authors:  Min Wook Joo; Yang-Guk Chung; Soo Young Hur; Ahwon Lee; Chan Kwon Jung; Won-Hee Jee; Jong Ho Kim
Journal:  World J Surg Oncol       Date:  2015-07-19       Impact factor: 2.754

7.  Do patients undergoing cytoreductive surgery and HIPEC for peritoneal malignancy need parenteral nutrition?

Authors:  David R Swain; Allison L Yates; Faheez Mohamed; Sanjeev P Dayal; Alexios Tzivanakis; Tom D Cecil; Brendan J Moran
Journal:  Pleura Peritoneum       Date:  2018-10-02

8.  Prevention of Venous Thromboembolism After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Development of a Physiotherapy Program.

Authors:  Xin-Bao Li; Kai-Wen Peng; Zhong-He Ji; Yang Yu; Gang Liu; Yan Li
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

Review 9.  The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions.

Authors:  Madeleine C Strach; Sarah Sutherland; Lisa G Horvath; Kate Mahon
Journal:  Ther Adv Med Oncol       Date:  2022-07-23       Impact factor: 5.485

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.